MapLight Therapeutics, Inc.
ML-021
Parkinson’s Disease
Date
TBD
Phase 1 readout · Date TBD estimated
What's at stake
Phase 1 trial results for ML-021 in Parkinson’s Disease are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Finalize preclinical candidate in 2027”